SAGE Therapeutics (SAGE) Gets a Hold Rating from Leerink Partners

In a report issued on April 12, Marc Goodman from Leerink Partners maintained a Hold rating on SAGE Therapeutics (SAGEResearch Report). The company’s shares closed last Wednesday at $77.67.

According to, Goodman is a 3-star analyst with an average return of 3.2% and a 47.7% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.

Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $97.85, implying a 27.1% upside from current levels. In a report issued on April 12, Raymond James also assigned a Hold rating to the stock.

See today’s analyst top recommended stocks >>

SAGE Therapeutics’ market cap is currently $4.46B and has a P/E ratio of 6.90. The company has a Price to Book ratio of 2.21.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.